-
Cell apoptosis and checkpoint suppression! Asain Pharma has partnered with Mercado to develop MDM2-p53 inhibitor APG-115/Keytruda for the treatment of solid tumors!
Time of Update: 2020-07-15
, July 06, 2020 / Biovalley BIOON/ Ascent Pharma is a China-based, global-oriented research and development of original new drug products in the clinical stage, dedicated to the development of innov
-
Her2 plus breast cancer heavy new drug! AstraZeneca/I-Sanantibodies-Drug Conjugate Enhertu EU Entry Review, Total Mitigation Rate 60.3%
Time of Update: 2020-07-15
, July 07, 2020 // Biovalley BIOON/--Daiichi Sankyo has announced that the European Medicines Agency (EMA) has accepted the of the new drug Enhertu (fam-trastuzumab deruxte), a new drug for breast
-
Cancer Res: Platelets can prevent cancer cell metastasis!
Time of Update: 2020-07-15
, July 6, 2020 /PRNewswire- bio-valley s/ scientists at Uppsala University have discovered a so-yet-unknown function of platelets in cancer In mouse models, these platelets have been shown to help
-
Nat Biomed Eng's new breakthrough! Systemic tracking of single cells with PET/CT imaging
Time of Update: 2020-07-15
, July 9, 2020 / Biovalley BIOON /- Living molecular imagery can detect the movement dynamics and movement of injected cells throughout the body, but most existing methods are unable to accurately a
-
Cancer: Surprise discovery! Vitamin D makes immunotherapy safer! Significantly reduce the toxic side effects of immune checkpoints!
Time of Update: 2020-07-15
, July 7, 2020 / PRNewswire/ -- Taking vitamin D supplements may help prevent serious side effects that a revolutionary anti-cancer treatment can have The findings were published in cancer, a peer-
-
Clini Cancer Research: Second generation ROS1-TKI, repotrectinib, anti-tumor activity of NSCLC for primary treatment or ROS1 mutation
Time of Update: 2020-07-14
Objective: Although the treatment of first-line keratosin has benefited patients with ROS1 and lung cancer, the incidence of ROS1-G2032R (ROS1G2032R) mutation and the progress of the central nervous
-
Cancer Immunol Immunother: New Research Explore dating For Ovarian Cancer
Time of Update: 2020-07-14
Standard treatment (SOC) for patients with ovarian cancer (OC) is plagued by high recurrence rates Several studies have shown that immune system semostally in changing the course of OC patients C
-
People are most afraid of sudden illness in middle age, and this rare tumor 'prefers' middle-aged people
Time of Update: 2020-07-14
People to middle-aged, often have old people, there are children, there are partners around, at this time the most afraid of illness And this is the true picture of 41-year-old Liu Lao Liu is from
-
Lancet Oncology: New pathway stymied for DNA repair drugs combined with chemotherapy can suppress ovarian cancer
Time of Update: 2020-07-14
High-level slurry ovarian cancer (HGSOC) is the most common type of ovarian epithelial cancer, the degree of malignancy is high, prone to metastasis, so most patients are in the advanced stage of
-
Multidisciplinary diagnosis and treatment is most suitable for use in the field of cancer treatment, the earlier the application, the better!
Time of Update: 2020-07-14
" Although the World Health Organization has long defined cancer as a chronic disease, the fear of cancer remains deeply rooted, not only because of its high mortality rate, but also because of the h
-
Nat BME: Methotrexate cell-derived microbubbles can relieve bile duct obstruction in patients with hepatic and extracellular bile duct cancer
Time of Update: 2020-07-14
Bile duct cancer is a type of epithelial malignant tumor, 5-year survival rate is particularly low, more than 90% of CAs from the hepatic bile duct, easy to form malignant bile duct obstruction Afte
-
ISA101b long peptide targets HPV16-positive cervical cancer, receives FDA-awarded orphan drug title
Time of Update: 2020-07-14
ISA Pharmaceuticals announced its main candidate, ISA101b, for the treatment of 16 type of human papillomavirus (HPV16) positive cervical cancer, and was awarded the title of "orphan drug" by the U.
-
Keytruda in conjunction with Lenvima for liver cell carcinoma (HCC): Encountering Waterloo
Time of Update: 2020-07-14
Merck and Japan's Aoki corporation signed today that FDA issued a complete response letter to requests for accelerated approval of Keytruda and Lenvatinib for first-line treatment of patients with
-
Targeting HER2 antibody drug conjugateENHERTU for breast cancer, gets quick review by the European Medicines Agency
Time of Update: 2020-07-14
Daiichi/AstraZeneca, Inc.,an antibody drug conjugate dating her2 ENHERTU (FAM-traszumab deruxtecan-nxki) for the treatment of breast cancer and obtained an accelerated review by the European Drug
-
Diabetes Care: Diabetics with pancreatitis have a higher risk of pancreatic cancer than people with type 2 diabetes
Time of Update: 2020-07-14
Pancreatitis and diabetes are recognized as risk factors for pancreatic cancer So far, however, the study has only looked at the risks associated with them individually A recent study published
-
Nat Commu: Colorectal near-end lymph node metastasis, from near to far?
Time of Update: 2020-07-14
Nature Communications published a research paper by the Center for Frontier Innovation in Biomedical Sciences (BIOPIC) at Peking University and the Bai Fan Group at the School of Life Sciences: Map
-
FDA approves Roche's breast cancer dual-targeted HER2 antibody combination: patobead monoyduminal and querta-supra
Time of Update: 2020-07-14
U.S regulators have approved a fixed dose combination of Roche Phesgo (Pertuzumab, patozumab) and Herceptin (Trastuzumab, qural beadmonotagalyses) and hyaluronic acid asse for the treatment of early
-
BI-RADS (Mammogram Reporting and Data System) Hierarchical Interpretation
Time of Update: 2020-07-14
Many patients have completed breast-related examination, for the report list on the BI-RADS rating do not understand, today we will briefyou BI-RADS (Mammograms Reporting and Data System) is divide
-
Gynecol Oncol: A Phase II study of eviemos and beva semostina in recurrent ovarian, peritoneal and fallopian tube cancers
Time of Update: 2020-07-14
Recurrent the possibility of , fallopian tube and peritoneal cancer senile cancer sourcing it with traditional therapy is limited Preliminary results from phase I studies of eviemos and bevalo semo
-
Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer
Time of Update: 2020-07-14
Whether angiokine -strain conversion enzyme (ACE) inhibitors and angiotensin receptor blockers will alter the risk of colorectal cancer remains debatable In a recent study published in the 's author